WASHINGTON, Aug 12- The U.S. Food and Drug Administration said on Monday it has approved GlaxoSmithKline Plc's drug Tivicay to treat the most common strain of HIV, the virus that causes AIDS. Tivicay is owned by ViiV Healthcare, an HIV joint venture between GSK, Pfizer Inc and Shionogi& Co Ltd in which GSK is the largest shareholder, with a 76.5 percent stake.» Read More
Aug 12- The U.S. Food and Drug Administration approved Tivicay, GlaxoSmithKline Plc's drug targeted at HIV-1, the most common strain of the virus that causes AIDS. The FDA also approved the use of the drug for children aged 12 years and over, who weigh at least 40 kilograms and who have not received treatment that has the same mechanism as the drug.» Read More
David Williamson, Healthcare Analyst, Motley Fool says the HIV infection cure for the U.S. toddler through early treatment will not work for adults. He explains why.
U.S. regulators approved a new AIDS treatment made by Merck, the first in a new class of drugs aimed at preventing replication of the virus, Merck said on Friday.
This meeting of the world's richest nations may be the most challenging one for the U.S. in years, given the growing power of Russia and China.
Today is World AIDS Day--and it comes at a time when health experts are considering new strategies in an attempt to change the environment of AIDS transmission. The rate of H-I-V infection is growing, with more than four million new cases each year. One biopharmaceutical company whose portfolio includes several HIV treatments--is Gilead Sciences.